Chemotherapeutics for Acute Erythroid Leukemia: Research, Present and Future
-
Published:2021-12-06
Issue:10
Volume:21
Page:819-831
-
ISSN:1566-5240
-
Container-title:Current Molecular Medicine
-
language:en
-
Short-container-title:CMM
Author:
Liao Zexi1,
Li Jiaxin1,
Wu Jingjing1,
Liu Jing1,
Sun Shuming1
Affiliation:
1. Molecular Biology Research Center, School of Life Sciences, Central South University, Changsha, 410078, China
Abstract
Acute erythroid leukemia (AEL) is a subtype of acute myeloid leukemia (AML)
with features such as accumulation of maturation-arrested erythroblasts. Compared with
AML, the progression of AEL is faster and the prognosis to available therapy is worse.
However, its categorization is still being updated and the pathophysiology of AEL is still
under research, making diagnosis and chemotherapy challenging for physicians. To
achieve better outcomes, therapies should be optimized and new drugs should be
developed. In this review, we summarize current strategies of diagnosis and therapies of
AEL, and discuss prospective targets for chemotherapeutic agents based on the
biological characteristics of AEL neoplastic cells as well as transcriptional factors and
pathways related to erythroid differentiation.
Publisher
Bentham Science Publishers Ltd.
Subject
Molecular Biology,Molecular Medicine,General Medicine,Biochemistry
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献